Dyslipidemia News and Research

RSS

Dyslipidemia is a disruption in the amount of lipids in the blood.

Phone, letter prompts improve statin uptake

Telephoning and writing to individuals who have not filled their new prescription for statin medication significantly improves rates of prescription uptake, show US study results.

30 Nov 2012

DARA BioSciences submits KRN5500 Orphan Drug Application with FDA

DARA BioSciences, Inc., a specialty pharmaceutical company focused on oncology and oncology supportive care products, announced today it has submitted an Orphan Drug Application to the U.S. Food and Drug Administration (FDA) for KRN5500, a compound in development to treat a painful form of chronic chemotherapy-induced peripheral neuropathy (CCIPN).

30 Nov 2012

Combining statin treatment with better fitness improves survival in people with dyslipidaemia

Taking statins or being even modestly physically fit markedly improves survival in people with dyslipidaemia (abnormal levels of harmful blood fats/cholesterol), according to new research published Online First in The Lancet. But combining statin treatment with better fitness may do more to ward off death than either intervention alone.

29 Nov 2012

Lupin’s Fenofibrate tablets now available in the U.S.

Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has launched its Fenofibrate Tablets, 48 mg and 145 mg strengths in the United States. Lupin had earlier received final approval for the same from the US Food and Drug Administration (FDA).

21 Nov 2012

Ligand Pharmaceuticals announces data from LG-7501 preclinical studies on HCV

Ligand Pharmaceuticals Incorporated announced that data from preclinical studies evaluating LG-7501 were featured in a poster presentation today at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases in Boston.

14 Nov 2012

Arisaph’s ARI-3037MO well tolerated in healthy male and female volunteers

Arisaph Pharmaceuticals, Inc. announced today during an oral presentation at the American Heart Association (AHA) meeting in Los Angeles, CA that its niacin analog, ARI-3037MO, was extremely well tolerated in a single-ascending dose (SAD) and a multiple-ascending dose (MAD) trial in healthy male and female volunteers.

7 Nov 2012

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.

7 Nov 2012

FDA accepts Sunovion’s two LATUDA sNDAs for review

Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental New Drug Applications (sNDAs) for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).

31 Oct 2012

Cardiovascular disease risk varies with HIV subgroup

The ability of lipids to predict risk for cardiovascular disease may be weakened in women who are infected with HIV, report researchers.

23 Oct 2012

Initiation of dinaciclib Phase 2b/3 CLL trial triggers $2M milestone payment from Merck

Ligand Pharmaceuticals Incorporated today announced that it will receive a $2 million milestone payment from Merck, known as MSD outside the United States and Canada, under the terms of a development and license collaboration for the development of dinaciclib.

22 Oct 2012

Liquid version of breast cancer drug Tamoxifen launched in the US

Breast Cancer Awareness Month raises visibility and research dollars to address a disease that in the United States claims nearly 40,000 lives annually and affects approximately 240,000 people who each year are newly diagnosed. While the month's activities are important in the fight against breast cancer, they are not designed to directly improve the day-to-day management of the disease.

22 Oct 2012

Gender gap in myocardial infarction mortality

Women are more likely to die from a myocardial infarction than men, according to research presented at the Acute Cardiac Care Congress 2012. The gender gap in mortality was independent of patient characteristics, revascularisation delays and revascularisation modalities.

20 Oct 2012

CKD may thicken carotid arteries, raise CVD risk in children

Findings from a US study show that carotid intima-media thickness is significantly higher among children with mild-to-moderate chronic kidney disease than in children without the kidney condition.

16 Oct 2012

Intensive treatment with high doses of statin drugs shows promise for dyslipidemia

A comprehensive new review on how to treat high cholesterol and other blood lipid problems suggests that intensive treatment with high doses of statin drugs is usually the best approach.

16 Oct 2012

ApoA-V as a contributor to dyslipidemia in obese children

Insulin may be an important regulator of serum apolipoprotein A-V levels in obese people and may contribute to the development of obesity-associated dyslipidemia, say Japanese researchers.

27 Sep 2012

New online, peer-reviewed journal on cardiovascular endocrinology

Wolters Kluwer Health is pleased to announce the publication of Cardiovascular Endocrinology, a new online, peer-reviewed journal committed to fostering effective collaboration between cardiologists and endocrinologists in addressing diabetes, hypertension, dyslipidemia, and related diseases and conditions.

24 Sep 2012

High uric acid precursor of obesity, metabolic syndrome

The relationship between uric acid and early cardiometabolic risk may precede obesity and the metabolic syndrome, show study findings.

20 Sep 2012

Obese adults with excess visceral fat, biomarkers of insulin resistance more likely to develop diabetes

Obese adults with excess visceral fat (fat located inside the abdominal cavity, around the body's internal organs) and biomarkers of insulin resistance had an associated increased risk for the development of type 2 diabetes mellitus, while obese individuals with higher amounts of total body fat and subcutaneous fat (underneath the skin) did not have this increased risk, according to a study in the September 19 issue of JAMA, and theme issue on obesity.

20 Sep 2012

Endocrine Society issues practice guideline for diagnosis and treatment of hypertriglyceridemia

The Endocrine Society today issued a Clinical Practice Guideline (CPG) for the diagnosis and treatment of hypertriglyceridemia. Triglycerides are a type of fat found in the blood and are associated with cardiovascular risk. The CPG, entitled "Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline" appears in the September 2012 issue of the Journal of Clinical Endocrinology and Metabolism (JCEM), a publication of The Endocrine Society.

10 Sep 2012

Vitamin D supplements have unintended lipid consequences

Correcting vitamin D levels in individuals at risk for cardiovascular disease may have detrimental effects on their lipid profiles, report researchers.

6 Sep 2012